← All trials
NCT05171946
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2022
- Primary completion
- Mar 1, 2023
- Completion date
- Jul 1, 2023
- First posted
- Dec 29, 2021
- Last posted
- Oct 19, 2022
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Imam Abdulrahman Bin Faisal UniversityLead sponsor
- ICONCollaborator
- Imam Abdulrahman Bin Faisal UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.